News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
668,669 Results
Type
Article (54529)
Company Profile (238)
Press Release (613902)
Multimedia
Podcasts (80)
Webinars (13)
Section
Business (187229)
Career Advice (2774)
Deals (34261)
Drug Delivery (114)
Drug Development (80843)
Employer Resources (171)
FDA (16754)
Job Trends (15637)
News (328211)
Policy (33156)
Tag
2024 BioCapital Digital (4)
2024 BioForest Digital (6)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (5)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (7)
2024 Genetown Digital (1)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (2)
Academia (2900)
Accelerated approval (6)
Adcomms (29)
Allergies (91)
Alliances (48158)
ALS (99)
Alzheimer's disease (1460)
Antibody-drug conjugate (ADC) (150)
Approvals (16726)
Artificial intelligence (276)
Autoimmune disease (28)
Automation (16)
Bankruptcy (347)
Best Places to Work (11979)
BIOSECURE Act (20)
Biosimilars (118)
Biotechnology (168)
Bladder cancer (84)
Brain cancer (30)
Breast cancer (293)
Cancer (2355)
Cardiovascular disease (198)
Career advice (2342)
Career pathing (33)
CAR-T (163)
Cell therapy (454)
Cervical cancer (20)
Clinical research (65825)
Collaboration (893)
Compensation (374)
Complete response letters (30)
COVID-19 (2834)
CRISPR (43)
C-suite (253)
Cystic fibrosis (107)
Data (2196)
Decentralized trials (2)
Denatured (19)
Depression (53)
Diabetes (283)
Diagnostics (6604)
Digital health (19)
Diversity (3)
Diversity, equity & inclusion (41)
Drug discovery (128)
Drug pricing (112)
Drug shortages (30)
Duchenne muscular dystrophy (101)
Earnings (71351)
Editorial (43)
Employer branding (23)
Employer resources (151)
Events (96166)
Executive appointments (754)
FDA (18027)
Featured Employer (47)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (794)
Gene editing (112)
Generative AI (25)
Gene therapy (333)
GLP-1 (816)
Government (4816)
Grass and pollen (6)
Guidances (53)
Healthcare (19548)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (139)
Indications (29)
Infectious disease (2992)
Inflammatory bowel disease (147)
Inflation Reduction Act (8)
Influenza (55)
Intellectual property (100)
Interviews (518)
IPO (15488)
IRA (42)
Job creations (4083)
Job search strategy (1957)
Kidney cancer (11)
Labor market (32)
Layoffs (529)
Leadership (22)
Legal (7542)
Liver cancer (80)
Lung cancer (336)
Lymphoma (153)
Machine learning (6)
Management (60)
Manufacturing (326)
MASH (70)
Medical device (13711)
Medtech (13716)
Mergers & acquisitions (19286)
Metabolic disorders (749)
Multiple sclerosis (84)
NASH (23)
Neurodegenerative disease (108)
Neuropsychiatric disorders (31)
Neuroscience (2041)
NextGen: Class of 2025 (6972)
Non-profit (4944)
Northern California (2562)
Now hiring (33)
Obesity (404)
Opinion (260)
Ovarian cancer (76)
Pain (95)
Pancreatic cancer (83)
Parkinson's disease (156)
Partnered (21)
Patents (238)
Patient recruitment (109)
Peanut (50)
People (56003)
Pharmaceutical (42)
Pharmacy benefit managers (20)
Phase I (20480)
Phase II (28776)
Phase III (21956)
Pipeline (1195)
Policy (156)
Postmarket research (2626)
Preclinical (8168)
Press Release (67)
Prostate cancer (109)
Psychedelics (35)
Radiopharmaceuticals (249)
Rare diseases (418)
Real estate (5882)
Recruiting (71)
Regulatory (23025)
Reports (35)
Research institute (2572)
Resumes & cover letters (419)
Rett syndrome (4)
RNA editing (4)
RSV (50)
Schizophrenia (77)
Series A (141)
Series B (89)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2299)
Special edition (16)
Spinal muscular atrophy (156)
Sponsored (31)
Startups (3672)
State (1)
Stomach cancer (16)
Supply chain (73)
Tariffs (37)
The Weekly (59)
United States (22168)
Vaccines (796)
Venture capitalists (43)
Weight loss (283)
Women's health (32)
Worklife (19)
Date
Today (211)
Last 7 days (815)
Last 30 days (2533)
Last 365 days (32959)
2025 (10234)
2024 (35153)
2023 (39825)
2022 (50670)
2021 (55189)
2020 (54344)
2019 (48057)
2018 (36794)
2017 (33385)
2016 (32545)
2015 (36951)
2014 (28664)
2013 (23787)
2012 (25494)
2011 (26225)
2010 (23595)
Location
Africa (944)
Alabama (56)
Alaska (7)
Arizona (185)
Arkansas (14)
Asia (39586)
Australia (6813)
California (5992)
Canada (1858)
China (528)
Colorado (267)
Connecticut (274)
Delaware (119)
Europe (91537)
Florida (848)
Georgia (207)
Hawaii (1)
Idaho (61)
Illinois (525)
India (28)
Indiana (323)
Iowa (9)
Japan (158)
Kansas (103)
Kentucky (25)
Louisiana (12)
Maine (69)
Maryland (857)
Massachusetts (4234)
Michigan (219)
Minnesota (366)
Mississippi (2)
Missouri (85)
Montana (27)
Nebraska (25)
Nevada (62)
New Hampshire (68)
New Jersey (1613)
New Mexico (31)
New York (1683)
North Carolina (982)
North Dakota (8)
Northern California (2562)
Ohio (188)
Oklahoma (14)
Oregon (36)
Pennsylvania (1271)
Puerto Rico (11)
Rhode Island (29)
South America (1309)
South Carolina (22)
South Dakota (1)
Southern California (2299)
Tennessee (101)
Texas (860)
Utah (187)
Virginia (148)
Washington D.C. (63)
Washington State (544)
West Virginia (3)
Wisconsin (55)
668,669 Results for "swiss advanced vision sav iol sa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
New Swiss Made Features for Cataract Surgery Lens Selection
The company Swiss Advanced Vision has announced the launch of New Features for its Toric Calculator improving the overall calculation experience.
February 22, 2024
·
2 min read
Biotech Beach
Centricity Vision Announces Commercial Launch of ZEPTOLink IOL Positioning System at AAO Conference
Centricity Vision Inc., a global ophthalmic technology company, announced the commercial launch of its ZEPTOLink IOL Positioning System™ at the American Academy of Ophthalmology Annual Meeting, November 3-6 in San Francisco.
November 1, 2023
·
4 min read
IPO
Swiss ADC Biotech Takes SPAC Track to NASDAQ
The deal is a blast from the not-too-distant past, when special purpose acquisition companies were an easy way for companies to list on the public market with a bundle of cash to operate on.
April 23, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
April 23, 2025
·
16 min read
Neuropsychiatric disorders
Newleos Raises $93.5M to Advance Neuropsychiatric Cast-Offs from Roche
Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.
February 13, 2025
·
3 min read
·
Dan Samorodnitsky
Biotech Beach
FDA Clears Centricity Vision’s ZEPTOLink IOL Positioning System
Centricity Vision Inc., a global ophthalmic technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the new ZEPTOLink™ IOL Positioning System.
May 3, 2023
·
3 min read
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
ObsEva SA announced that the Regulatory Board of SIX Swiss Exchange has granted the delisting of the shares of the company from SIX Swiss Exchange and has exempted the company from certain obligations associated with the maintenance of the listing.
April 3, 2024
·
2 min read
Press Releases
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
April 15, 2025
·
5 min read
Press Releases
A New VISION: Groundbreaking Collaboration Advances Whole Eye Transplants
December 5, 2024
·
4 min read
Press Releases
Sapio Sciences Expands Collaboration With AWS to Advance Science-Aware AI Vision
October 29, 2024
·
3 min read
1 of 66,867
Next
